机构:[1]Department of Gastroenterology, the Second Affiliated Hospital of Guangzhou University of Traditional Chinese Medicine, Guangzhou, China.大德路总院肛肠科大德路总院肛肠科广东省中医院[2]The Second Clinical Medical College of Guangzhou University of Traditional Chinese Medicine, Guangzhou, China.广东省中医院[3]Department of Gastroenterology, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, China中山大学附属第六医院[4]Guangdong Provincial Key Laboratory of Colorectal and Pelvic Floor Diseases, the Sixth Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.中山大学附属第六医院
Infliximab is an effective drug for the treatment of Crohn's disease. As a rare and unique adverse effect of infliximab, hypertension should be paid enough attention in clinical work. At present, there is no relevant case report. We report a case of a 38-year-old man with Crohn's disease who had no history of hypertension and developed hypertension symptoms during infliximab treatment.The patient was treated with 5 mg/kg infliximab on August 27, 2020. From August 27, 2020 to October 20, 2020, the patient underwent 3 treatment sessions. After each injection of infliximab, the patient's blood pressure became elevated, accompanied by dizziness and symmetrical numbness of both lower limbs. Amlodipine benazepril tablets were given orally to control blood pressure. Under close monitoring, 5 mg/kg infliximab was used again. After 10 min of infusion, blood pressure rose to 160/118 mmHg. Infusion was discontinued immediately, after which blood pressure decreased to normal. Adrenal computed tomography did not indicate adrenal hyperplasia or space occupying lesions, and the detection of hypertension related indicators in standing and supine position was abnormal. Since follow up, the patient has stopped using infliximab and has had no hypertension-related symptoms, even without antihypertensives. Measured blood pressure was within the normal range.Hypertension, as one of the rare adverse reactions of infliximab in the treatment of Crohn's disease, should be paid enough attention.
基金:
This work was supported by the 13th Zhaoyang
Talent Project of Guangdong Provincial Hospital of
Traditional Chinese Medicine (No. 2Y2022YL29) and
the Special Project of Science and Technology Innovation
Strategy of Guangdong Province (No. pdjh2021b0123).
第一作者机构:[1]Department of Gastroenterology, the Second Affiliated Hospital of Guangzhou University of Traditional Chinese Medicine, Guangzhou, China.
共同第一作者:
通讯作者:
通讯机构:[3]Department of Gastroenterology, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, China[4]Guangdong Provincial Key Laboratory of Colorectal and Pelvic Floor Diseases, the Sixth Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.[*1]Department of Gastroenterology, the Sixth Affiliated Hospital, Sun Yat-sen University, 26 Yuancunerheng Road,Guangzhou 510655, China.
推荐引用方式(GB/T 7714):
Zhao Xiying,Mo Jiahao,Zhang Beiping,et al.Hypertension as a rare adverse effect caused by infliximab in the treatment of Crohn's disease: a case report[J].Annals Of Palliative Medicine.2022,11(9):3001-3004.doi:10.21037/apm-22-807.
APA:
Zhao Xiying,Mo Jiahao,Zhang Beiping&Tang Jian.(2022).Hypertension as a rare adverse effect caused by infliximab in the treatment of Crohn's disease: a case report.Annals Of Palliative Medicine,11,(9)
MLA:
Zhao Xiying,et al."Hypertension as a rare adverse effect caused by infliximab in the treatment of Crohn's disease: a case report".Annals Of Palliative Medicine 11..9(2022):3001-3004